Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002337 · ClinicalTrials.gov registry record · Phase 1
A Study of Multiple Doses of Vesnarinone in Advanced HIV Disease
A Phase 1 study, sponsored by Otsuka America Pharmaceutical.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT00002337 is a Phase 1 study that has completed, run by Otsuka America Pharmaceutical. The registered enrollment target is 56 participants.
The verdict
NCT00002337, a Phase 1 study, has completed, sponsored by Otsuka America Pharmaceutical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
To evaluate the safety and tolerability of four doses of oral vesnarinone in patients with advanced HIV disease.
Interventions
- DRUG Vesnarinone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002337
The ClinicalTrials.gov registry entry for NCT00002337 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka America Pharmaceutical, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vesnarinone is the first listed.
NCT00002337 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002337 about?
NCT00002337 is a clinical study titled "A Study of Multiple Doses of Vesnarinone in Advanced HIV Disease". To evaluate the safety and tolerability of four doses of oral vesnarinone in patients with advanced HIV disease.
What is the current status of trial NCT00002337?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants.
What interventions are being tested in trial NCT00002337?
The interventions under investigation include: Vesnarinone (DRUG).
Who is sponsoring clinical trial NCT00002337?
This trial is sponsored by Otsuka America Pharmaceutical, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.